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Posttranslational modifications (PTMs) occur to nearly all proteins, are catalyzed by specific en-
zymes, and are subjected to tight regulation. They have been shown to be a powerful means by
which the function of proteins can bemodified, resulting in diverse effects. Technological advances
such as the increased sensitivity of mass spectrometry–based techniques and availability of mutant
animal models have enhanced our understanding of the complexities of their regulation and the
effect they have onprotein function. However, the role that PTMs have in a pathological context still
remains unknown for the most part. PTMs enable the modulation of nuclear receptor function
in a rapid and reversible manner in response to varied stimuli, thereby dramatically altering their
activity in some cases. This review focuses on acetylation, phosphorylation, SUMOylation, and
O-GlcNAcylation, which are the 4 most studied PTMs affecting lipid-regulated nuclear receptor
biology, as well as on the implications of such modifications on metabolic pathways under ho-
meostatic and pathological situations. Moreover, we review recent studies on the modulation of
PTMs as therapeutic targets for metabolic diseases. (Endocrinology 158: 213–225, 2017)
Posttranslational modifications (PTMs), or the co-valent modification of a protein catalyzed by en-
zymes, increase the functional diversity of proteins. To
aid the scientific community in keeping updated with the
number and abundance of modifications, resources such
as PTMCuration have been created (1, 2).More than 200
different PTMs have been described so far for both
prokaryotic and eukaryotic cells, including ubiquitination,
phosphorylation, glycosylation, acetylation, and meth-
ylation (3, 4). The discovery of new methodologies and
tools to identify PTMs, for example, antibodies specifi-
cally recognizing modified residues, proximity ligation
assays (5), and the refinement of mass spectrometry–
based techniques (6, 7), have allowed us to more easily
further our understanding of how these processes are
regulated endogenously and how they impact protein–
protein interactions. Moreover, gene targeting ap-
proaches have also facilitated the study of their impact on
mammalian physiology (8).
Nuclear receptors (NRs) are sequence-specific tran-
scription factors primarily regulated through ligand
binding. PTMs allow for NR modulation in a fast, re-
versible manner, inducing specific molecular changes in
response to several stimuli that further regulate the re-
ceptor’s activity. It has become evident that complex
relationships exist between different types of PTMs,
which may function in a cooperative or competitive
manner (9, 10). This review focuses on the 4most studied
PTMs affecting lipid-regulated NR biology excluding the
peroxisome proliferator–activated receptors (PPARs),
which have been extensively reviewed elsewhere (11–14).
Posttranslational modifications
Acetylation of lysine residues was initially identified
in histones for their critical role in the control of gene ex-
pression (15). Enzymes that add or remove acetyl groups
from proteins are named histone acetyltransferases and
histone deacetylases (HDACs), respectively. Approximately
ISSN Print 0013-7227 ISSN Online 1945-7170
Printed in USA
This article has been published under the terms of the Creative Commons Attribution
License (CC-BY; https://creativecommons.org/licenses/by/4.0/), which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source
are credited. Copyright for this article is retained by the author(s).
Received 12 August 2016. Accepted 2 December 2016.
First Published Online 7 December 2016
Abbreviations: ABCA1, adenosine triphosphate–binding cassette transporter A1; AF,
activation function; AMPK, adenosine monophosphate protein kinase; FAS, fatty acid
synthase; FXR, farnesoid X receptor; GlcNAc, b-N-acetylglucosamine; HDAC, histone
deacetylase; HDL, high-density lipoprotein; LRH-1, liver receptor homolog-1; LXR, liver X
receptor; NCoR, nuclear receptor corepressor; NR, nuclear receptor; PIAS, protein inhibitor
of activated signal transducer and activator of transcription; PPAR, peroxisome
proliferator–activated receptor; PTM, posttranslational modification; RXR, retinoid X re-
ceptor; SIRT1, sirtuin 1; SUMO, small ubiquitin-like modifier.
doi: 10.1210/en.2016-1577 Endocrinology, February 2017, 158(2):213–225 press.endocrine.org/journal/endo 213
85% of all eukaryotic nonhistone proteins are acetylated
(16). In mammals, there are 2 different families of HDACs,
that is, the classical HDAC family (comprisingHDACs 1 to
10) and the sirtuin family of nicotinamide adenine di-
nucleotide+–dependent deacetylases, also known as type III
HDACs (16). HDACs can act as part of large multiprotein
complexes. For example, HDAC1 andHDAC2 are present
in the Sin3 complex, where they interact with the NR co-
repressor (NCoR) (17) and silencing mediator of retinoic
acid and thyroid hormone receptor (18) corepressors.
HDAC3 also binds these corepressors, albeit within
distinct complexes (19, 20).
Emerging evidence shows that the acetylated state of
nuclear proteins, such as NRs including the farnesoid X
receptor (FXR) and the liver X receptor (LXR), is reg-
ulated in response to several metabolites and cofactors,
including nicotinamide adenine dinucleotide+ and acetyl
coenzyme A (21). Indeed, protein acetylation is altered in
obese individuals (22, 23), supporting the link between
dysregulation of PTMs and metabolic disease.
GlcNAcylation is the addition and removal of a single
sugar modification, O-linked b-N-acetylglucosamine
(GlcNAc), to the hydroxyl groups of serine and/or
threonine residues of target proteins. Most of this
modification is found on intracellular proteins, and
about a fourth of all identifiedO-GlcNAcylated proteins
are involved in transcription or translation (24).
GlcNAcylation is catalyzed by uridine diphospho-N-
acetylglucosamine:polypeptide b-N-acetylglucosaminyl-
transferase and removed byO-GlcNAcase in response to
several energetic and nutritional stimuli, including glu-
cose (25) and phosphatidylinositol-3,4,5-trisphosphate
(26), a mediator in the insulin signaling pathway. The
activity of these enzymes is strictly regulated and several
pathologies have been linked to aberrant GlcNAcylation,
including Alzheimer’s disease and insulin resistance (24).
Phosphorylation is defined as the covalent modification
of phosphate groups to specific amino acids, with the most
common in eukaryotic cells being serine, threonine, and
tyrosine. Phosphorylation is catalyzed by kinases, and re-
moval of phosphate groups is performed by phosphatases.
These processes regulate almost every basic cellular process
(27). Phosphorylation of NRs can alter protein–protein
interactions, protein conformation, and binding of the re-
ceptor to DNA, thus affecting their transcriptional activity
(28). The complex crosstalk between protein phosphory-
lation and metabolism has been reviewed recently (29).
BothO-GlcNAcylation and phosphorylation occur at
serine and threonine residues and thus can compete for
the same or adjacent sites within the same protein. This
can occur in a reciprocal manner or synergistically,
resulting in a complex interplay that may lead to multiple
regulatory scenarios (30, 31).
SUMOylation is the covalent binding or conjugation
of members of the small ubiquitin-like modifier (SUMO)
family to proteins. In mammals, the SUMO family
consists of 3members: SUMO-1, SUMO-2, and SUMO-3
(32). SUMOylation is reversible and uses a specific set of
enzymes for processing and attachment—such as the E1
SUMO-activating enzyme subunits 1/2 ormembers of the
E3 ligases protein inhibitor of activated signal transducer
and activator of transcription (PIAS) family (33)—and
removal, known as SUMO peptidases. In mammals, the
enzymes responsible for SUMO removal are referred to as
sentrin-specific proteases, deSUMOylating isopeptidases
1 and 2 (34), as well as ubiquitin-specific protease–like 1
(35). How intracellular metabolism regulates protein
SUMOylation requires further study.
Posttranslational Modifications of NRs
FXR
FXR regulates the expression of numerous genes in
response to certain bile acids to regulate bile acid, lipid,
and glucose homeostasis (36). Consistent with its met-
abolic role, this receptor is highly expressed in the liver
and small intestine. The modulation of FXR activity is
currently being studied for the treatment of metabolic
diseases such as dyslipidemia, insulin resistance (37, 38),
and nonalcoholic fatty liver disease (39).
FXR acetylation
p300 regulates FXR transactivation through acetyla-
tion of histones at the promoters of some of its target
genes and of the receptor itself [Figs. 1 and 2(A)] (40). The
acetylase activity of p300 is increased by FXR agonists,
and its inhibition significantly reduces the expression of
small heterodimer partner, a well-established FXR target
gene that also regulates bile acid synthesis enzymes.
Recently, contrasting data have shown that FXR acety-
lation at lysine 217 and lysine 157 increases protein
stabilization but decreases FXR heterodimerization with
retinoid X receptor (RXR)a and DNA binding, reducing
in turn its transactivation capacity (Fig. 1; Table 1) (23).
In this way, the p300 acetyltransferase plays a dual role
by first initiating FXR target gene expression by acety-
lating H3 histones, followed by limiting FXR activity by
inducing the receptor’s acetylation, which weakens its
association with DNA. This process is reciprocally reg-
ulated by the sirtuin 1 (SIRT1) deacetylase. Down-
regulation of endogenously expressed SIRT1 in mouse
liver increases acetylation of FXR [Fig. 2(A)]. Conversely,
activation of SIRT1 by resveratrol reduces acetylation of
FXR in obese mice, leading to an improved metabolic
profile. In this model, FXR activity is tightly regulated by
the opposing actions of p300 and SIRT1, and this
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dynamic mechanism has been proposed to be dysregu-
lated in metabolic diseases (Table 1). However, the
metabolic outcome seen on the SIRT1-deficient mice
could also be explained by effects on other NRs targeted
by this deacetylase, including the LXRs (50). Investiga-
tions using FXR mutant knock-in models with altered
lysine acetylation continue to help us understand the
impact of FXR acetylation on metabolic diseases such
as obesity (41).
FXR phosphorylation
FXR can be phosphorylated at serine 135 and serine
154 by protein kinase C (42). These residues are situated
in the DNA-binding domain of the receptor (Fig. 1), and
their phosphorylation increases binding to the PPARg
coactivator 1a, leading to enhanced FXR transcriptional
activity without affecting DNA binding or subcellular
localization [Fig. 2(A); Table 1] (42).
Shneider et al. (69) also reported increased activity of
FXR by phosphorylation, showing that function and
nuclear localization of FXR are regulated by adenosine
triphosphatase class 1 type 8B member (also known as
FIC1). Mutations in this adenosine triphosphatase re-
sult in progressive familial intrahepatic cholestasis type 1
and benign recurrent intrahepatic cholestasis (70), both
caused by the accumulation of hepatic
bile acids ultimately resulting in liver
failure. In this study, the authors argue
that protein kinase Cz–mediated phos-
phorylation of FXR is initially induced
by FIC1, which, in turn, lea1ds to the
enhanced transcription of FXR target
genes.
Recently, adenosine monophosphate
protein kinase (AMPK) was shown
to directly interact and phosphorylate
FXR at serine 250 (Fig. 1) (43). Acti-
vation of AMPK by metformin, a
commonly used drug for the treatment
of type 2 diabetes, leads to the in-
hibition of FXR transcriptional activity
by impairing coactivator binding. Re-
duced FXR target gene expression by
metformin-activated AMPK decreases
fecal bile acid excretion in wild-type
mice, and it aggravates liver injury
in an animal model of intrahepatic
cholestasis (43).
Overall, these results demonstrate
the complexity of FXR regulation by
phosphorylation, with different ki-
nases acting on different residues and
having opposite outcomes, which high-
lights the role of this modification on the aberrant activity
of FXR and its potential role in bile acid–related diseases
(Table 1).
FXR SUMOylation
FXR is SUMOylated by SUMO1 in vitro and in vivo
on 2 residues: K122 and K275 (Fig. 1) (44). SUMOylation
reduces FXR ligand–induced transactivation and re-
cruitment to its target gene promoters without affecting
its nuclear localization [Fig. 2(A)]. A recent study showed
that ligand-induced SUMO2-FXR is necessary for the
transrepression of several proinflammatory genes (41), a
process that does not involve the direct binding of FXR to
DNA [Fig. 2(A)]. Furthermore, in a mouse model of diet-
induced obesity, hepatic FXR is strongly acetylated at
K217. Using a mutant version of FXR mimicking acet-
ylated K217 in lean mice (K217Q), this study demon-
strated that enhanced FXR acetylation induced the
expression of several hepatic proinflammatory genes,
leading to increased macrophage infiltration, which was
inversely correlated with the levels of sumoylated FXR
[Fig. 2(B); Table 1] (41). This is partly due to decreased
interaction between FXR and the SUMO-conjugating
enzyme PIASg. This work not only proved how differ-
ent PTMs can act in the regulation of NR activity in a
Figure 1. Posttranslational modifications on lipid-activated NRs. Residues modified by
acetylation (dark gray), phosphorylation (light gray), and SUMOylation (black) are shown.
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coordinated manner, but it also provided evidence of the
therapeutic potential of modulating PTMs, whereby
targeting (inhibiting) FXR acetylation at K217 leading to
the SUMOylation of the receptor could result in ame-
liorated hepatic inflammation and increased glucose
tolerance in obese individuals, as shown in animal models
of the disease.
FXR O-GlcNAcylation
FXR was recently demonstrated to be O-GlcNAcylated
at its N-terminal activation function (AF)-1 domain
via O-GlcNAc transferase. O-GlcNAcylation increases
FXR expression, transcriptional activity, and stability
while retaining its nuclear localization (71). It was spec-
ulated that at low glucose concentrations FXR binds to ac-
tive corepressor complexes, which may be then modulated
when FXR is O-GlcNAcylated at high
glucose concentrations. However, the
exact mechanism underlying the en-
hanced transcriptional activation re-
mains to be elucidated.
Intriguingly, O-GlcNAcylation of
LXR (see later) and activation of 2 other
transcription factors, that is, carbohydrate-
responsive element-binding protein (72)
and sterol-responsive element-binding
protein 1 (73), induce the expression
of fatty acid synthase (FAS), whose
dysregulation has been linked to the
pathogenesis of metabolic diseases (74).
On the contrary, O-GlcNAcylation of
FXR has the opposite effect—reducing
FAS expression. Details of this balancing
act of FXR O-GlcNAcylation over the
modification of these other regulators of
FAS expression remain to be identified.
FXR not only plays an important
metabolic role, but it also elicits strong
anti-inflammatory properties (75, 76).
Targeting the receptor’s activity with a
full agonist may lead to serious side
effects, such as a decrease in circulating
high-density lipoprotein (HDL) levels
and systemic cholesterol accumulation
as a consequence of reduced bile acid
synthesis (77). Indeed, a recent clinical
trial assessing the efficacy of the potent
FXR activator obeticholic acid for the
treatment of steatohepatitis was inter-
rupted, partly due to induced lipid ab-
normalities in obeticholic acid–treated
patients, including increased circulating
total cholesterol and low-density lipo-
protein with decreased HDL (78). Therefore, selective
modulation of FXR function by tissue-specific agonists
or altering its posttranslational modifications could prove
to be alternative effective therapeutic approaches.
Liver receptor homolog-1
Liver receptor homolog-1 (LRH-1), also known as
fetoprotein transcription factor, is an orphan NR
member of the fushi tarazu factor-1 subfamily. It is
highly expressed in the intestine and liver, where it plays
several functions ranging from development to choles-
terol and bile acid homeostasis (79). In contrast to other
lipid-activated NRs, including LXR and FXR, LRH-1
binds with high affinity as a monomer to its DNA re-
sponse elements to induce transcription of its target
genes.
Figure 2. Changes in posttranslational modifications and their effects on FXR activity under
physiological (A) or pathological (B) conditions. In homeostatic conditions (A), there is a tight
regulation between p300-mediated acetylation and Sirt1-mediated deacetylation of FXR. In
parallel, other modifications such as phosphorylation and SUMOylation have also been
proven to regulate FXR actions. However, a pathological increase in FXR acetylation (B) and
subsequent dysregulated FXR activity leads to increased inflammatory gene expression and
decreased target gene expression.
216 Becares et al Posttranslational Changes in Nuclear Receptors Endocrinology, February 2017, 158(2):213–225
LRH-1 phosphorylation
LRH-1 is phosphorylated at several serine residues
located in its hinge and ligand-binding domains by the
mitogen-activated protein kinase extracellular signal-
regulated kinases (45). These include serine 238 and
serine 243 (Fig. 1), whose phosphorylation is induced by
phorbol myristate acetate stimulation in both hepatic
HepG2 and adenocarcinoma HeLa cells to increase the
receptor’s transactivation activity (Table 1). LRH-1
phosphorylation by extracellular signal–regulated ki-
nase may implicate a novel role for this receptor in
proliferation in response to mitogenic stimuli.
Table 1. Summary of NR Posttranslational Modifications to Date
Nuclear
Receptor Modification Residue Mechanism Effect on Activity In Vivo Effects References
FXR Acetylation Lys157 Increase protein
stabilization
↓ Present in livers of
obese mice,
increases hepatic
inflammation
Fang et al.,
2008 (40);
Kemper et al.,
2009 (23);
Kim et al.,
2015 (41)
Lys217 Decreased
heterodimerization
and DNA binding
Phosphorylation Ser135 Increased binding to
coactivator
↑ Decrease leads to
bile acid accumulation
and hepatic failure
Gineste et al.,
2008 (42)
Ser154 Nuclear localization
Ser250 Decreased binding to
coactivator
↓ Induction leads to
bile acid accumulation
and hepatic injury
Lien et al.,
2014 (43)
SUMOylation Lys122
(SUMO1)
Decreased recruitment to
gene promoters
↓ Transactivation Ameliorates hepatic
inflammation and improves
metabolic phenotype in
obese mice with
hyperacetylated FXR
Balasubramaniyan
et al., 2013 (44);
Kim et al.,
2015 (41)
Lys275
(SUMO1
and
SUMO2)
Increased interaction with
nuclear factor kB
↑ Transrepression
LRH-1 Phosphorylation Ser238 Unknown ↑ Lee et al.,
2006 (45)Ser243
SUMOylation Lys224 Increased correpressor
interaction
↑ Transrepression Loss at K289 leads to
increased reverse
cholesterol transport and
diminished development of
atherosclerosis in mice
Chalkiadaki and
Talianidas,
2005 (46);
Stein et al.,
2014 (47);
Venteclef et al.,
2010 (48)
Lys289 Increased correpressor
interaction
↓
LXRs Deacetylation Lys432 (LXRa) Ubiquitination of receptor ↑ Deficiency causes impaired
lipid metabolism and
decrease in plasma HDL
levels in mice
Defour et al.,
2012 (49);
Li et al.,
2007 (50)
Lys433 (LXRb)
Phosphorylation Ser198 (LXRa) NCoR recruitment ↓ (Gene specific) Decrease leads to reduction
in hepatic fat in mice on a
high-fat diet
Chen et al.,
2006 (51);
Cho et al.,
2015 (52);
Hwahng et al.,
2009 (53);
Torra et al.,
2008 (54);
Yamamoto et al.,
2007 (55);
Wu et al.,
2015 (56)
Thr290 Decreased DNA binding ↓ Induction caused reduction of
circulating cortisol and
glucose in rats
Ser291 Reduced coactivator and
increased corepressor
recruitment
SUMOylation Lys328, 434
(LXRa)
Increased correpressor
interaction
↑ Transrepression Ghisletti et al.,
2007 (57);
Huang et al.,
2011 (58);
Pascual-Garcı´a et al.,
2013 (59)
Lys410, 448
(LXRb)
RXRs Acetylation Lys125
(RXRa)
Increased DNA binding ↑ Zhao et al.,
2007 (60)
Phosphorylation Ser260
(RXRa)
Reduced heterodimerization
and cofactor recruitment
↓ Receptor’s resistance to
degradation is strongly
liked to cell malignancy
Macoritto et al.,
2008 (61);
Matsushima-Nishiwaki
et al., 1996 (62);
Zimmerman et al.,
2006 (63);
Yoshimura et al.,
2007 (64);
Adachi et al.,
2002 (65);
Bruck et al.,
2005 (66)
SUMOylation Lys108
(RXRa)
Unknown ↓ Choi et al.,
2006 (67);
Schneider et al.,
2013 (68)
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LRH-1 SUMOylation
LRH-1 SUMOylation, by SUMO-1, was first de-
scribed at lysine 224, located in the hinge region of the
receptor (Fig. 1). This causes the protein to be sequestered
into nuclear bodies, inhibiting its transcriptional capacity
(Table 1) (46). A later study showed that this modifi-
cation is also responsible for inducing LRH-1’s trans-
repressive activity in vitro and in a mouse model of
hepatic acute phase response (48). The transrepression
elicited upon LRH-1 SUMOylation requires the presence
of the NCoR subunit G protein pathway suppressor 2,
which acts as a docking site stabilizing its interaction with
the NCoR1/HDAC3 corepressor complex. Additionally,
in an acute phase response setting ligand-activated LXRb
suppresses the expression of inflammatory genes, which
is mediated through SUMOylation of the LRH-1 receptor
(57, 80). This poses the idea of SUMOylation as a
common mechanism that may regulate the crosstalk
between the transrepressive activities of different NRs,
as has been shown for PPARg and LXR (57, 80).
Further evidence for a pathophysiological role for
LRH-1 SUMOylation has now been provided in the
context of cardiovascular disease. Loss of LRH-1
SUMOylation at residue lysine 289 leads to an in-
creased reverse cholesterol transport and reduced
atherosclerosis in the low-density lipoprotein receptor
knockout mouse model (Table 1) (47). This is accom-
panied by the increased expression of a subset of LRH-1
target genes, mainly involved in hepatic cholesterol ho-
meostasis. This gene-selective effect on expression
was explained by the reduced binding of the non-
SUMOylatable LRH-1–K289R form to the prospero
homeobox protein 1 corepressor. This study is highly
relevant as one of the very few directly addressing the
impact of changes in NR modifications on disease pro-
gression at a whole-body level.
Owing to LRH-1 effects on bile acid, cholesterol, and
glucose homeostasis, this receptor has been considered a
potential therapeutic target for the treatment ofmetabolic
diseases, especially in liver, where it is highly expressed.
However, how PTMs specifically regulate LRH-1 activity
in vivo needs to be confirmed with further studies. It also
remains to be investigated whether other PTMs such as
acetylation play a role in finely tuning the activity of
this receptor.
LXRs
The LXR family consists of 2 different isotypes, LXRa
and LXRb, with their names deriving from the initial
isolation of the LXRa isotype from human liver (81, 82).
The 2 isotypes share ;75% sequence homology in both
their DNA-binding domain and ligand-binding domain,
and they differ mainly on their N-terminal sequence and
their expression pattern (83). LXRa is predominantly
expressed in liver and other metabolically active tissues
and cell types, such as kidney, intestine, and macro-
phages, whereas LXRb is ubiquitously expressed. Both
LXRs regulate transcription by forming permissive
heterodimers with RXR (84), that is, they can be acti-
vated by ligands for each heterodimeric partner. LXRs
are physiologically activated primarily by oxidized me-
tabolites of cholesterol (84, 85), the cholesterol precursor
desmosterol (86, 87), as well as a number of synthetic
ligands (88, 89). These receptors play a crucial role in the
regulation of cholesterol and fatty acid homeostasis (90)
but also act as modulators of inflammation and immunity
(91). Therefore, they are promising targets for the treat-
ment of several pathologies with a metabolic and in-
flammatory component, such as atherosclerosis (92). A
number of PTMs have now been reported to regulate their
stability and transcriptional capacity.
LXR acetylation
Removal of acetyl groups from lysines in LXRs by the
SIRT1 deacetylase (at K432 in LXRa andK433 in LXRb,
Fig. 1) promotes the receptor’s ubiquitination and sub-
sequent degradation by the proteasome, while being a
positive regulator of its transcriptional activation [Fig.
3(A); Table 1] (50). Li et al. (50) suggested that ligand-
dependent deacetylation of LXR and consequent deg-
radation leads to its clearance from gene promoters,
which facilitates the next round of transcription and thus
increases the expression of its target genes. Interestingly,
this study also demonstrated that animals deficient in
Sirt1 showed higher levels of LXRA protein and dis-
played impaired lipid metabolism and defective reverse
cholesterol transport in part due to reduced Abca1 ex-
pression and subsequent decrease in HDL levels, as well
as increased hepatic and testicular cholesterol levels
(Table 1). This mechanism was further supported by a
study in human skeletal muscle where SIRT1 was shown
to regulate the expression of the lipogenic LXR target
gene Srebp1c (49).
LXR O-GlcNAcylation
Albeit controversial, a study claiming that glucose is
capable of activating LXRs and act as their ligand at
physiological concentrations raised new insights into how
LXR activity may be directly regulated by other mecha-
nisms besides ligand binding (93). This was followed by
a study on human hepatic cells and an animal model of
streptozotocin-induced insulitis and diabetes in which it
was reported that LXRs undergo O-GlcNacylation
in response to glucose in vitro or by refeeding in vivo
[Fig. 3(A)] (94). The authors propose that previously re-
ported effects by glucose (93), a hydrophilic compound,
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were caused by its downstream signaling, presumably
through posttranslational modifications, rather than the
direct binding to the LXR highly hydrophobic ligand-
binding domain. This study also argues that this modifi-
cation affects the expression of the lipogenic transcription
factor Srebp1c, although the exact mechanisms through
which O-GlcNacylation regulates LXR activity need to
be further elucidated.
LXR phosphorylation
LXRa is phosphorylated at serine 198 (Fig. 1) (Ser198
or Ser196 in the human and murine sequence, re-
spectively) both in vitro and in atherosclerotic plaques
of apolipoprotein E–deficient mice (51, 54, 56). This
modulates LXRa transcriptional activity in a gene-
selective manner [Fig. 3(A); Table 1] and is enhanced
by both endogenous [24(S),25-epoxycholesterol] and
synthetic (T0901317 and GW3965) LXR ligands (54,
56). In a murine macrophage cell line stably expressing
LXRa, ligands for the RXR receptor such as the 9-cis–
retinoic acid and bexarotene inhibited Ser198 phos-
phorylation, leading to changes in LXR/RXR-regulated
gene expression, particularly on genes sensitive to
changes in LXRa phosphorylation at this residue, such as
Ccl24 (54). The Ser198 residue is located in the hinge
region of LXRa and was shown to be targeted by casein
kinase 2 (54). Peptide molecular modeling studies suggest
that Ser198 phosphorylation affects LXRa conforma-
tion, possibly influencing the recruitment of cofactors,
such as NCoR (54, 56). Further evidence also supports
these gene-selective changes by LXRa phosphorylation.
For instance, macrophage expression of CCR7 ismarkedly
induced by LXRa when the receptor is not phosphorylated
at Ser198 (56). This is associated with decreased levels of
chromatin repression marks (H3K9me3 and H3K27me3)
at theCcr7 locus in cells expressing the nonphosphorylated
version of the receptor.
Phosphorylation of LXRa by other kinases, including
protein kinase A, has been reported at several residues
(Ser195, Ser196, Thr290, Ser291) (Fig. 1) in rat primary
hepatocytes and mouse liver, although detailed muta-
genesis studies were not performed (55). Protein kinase
A–mediated phosphorylation of LXRa leads to the re-
pression of Srebp1c expression, a well-established LXR
target gene, caused by decreased binding of the RXR/
LXRa heterodimer to DNA, as well as reduced coac-
tivator (steroid receptor coactivator-1) and increased
corepressor (NCoR) occupancy (Table 1). The regulation
of LXRa phosphorylation by cholesterol and oxysterols
(54) prompted other studies investigating the effect
of nutrient-regulated kinases. Oltipraz [4-methyl-5-(2-
pyrazinyl)-1,2-dithiole-3-thione] is a member of the
dithiolethione family, a series of compounds naturally
found in cruciferous vegetables with a broad range of
therapeutic uses, including chemoprevention (95) and
liver fibrosis (96). Interestingly, oltipraz attenuates LXRa
phosphorylation at an unspecified serine residue inmouse
liver through the inhibition of p70 ribosomal S6 kinase-1
(53), a major downstream effector of the mammalian
target of rapamycin signaling pathway. This decrease in
LXRa serine phosphorylation leads to a reduction in
Srebp1c target gene expression in culture. Addition-
ally, oltipraz administration to mice fed a high-fat diet
caused a decrease in hepatic fat content, pointing to
oltipraz and the modulation of LXR phosphorylation as
potential therapeutic targets for the treatment of fatty
Figure 3. Effects of posttranslational modifications on LXR transcriptional activation (A) and transrepression (B). (A) Deacetylation by LXR agonists
or O-GlcNAcylation by glucose induces LXR target gene expression, whereas phosphorylation has a gene-specific effect. (B) LXR transrepression of
inflammatory gene expression is promoted by SUMOylation of the receptor, which consequently increases LXR avidity for the NCoR complex.
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liver. Furthermore, a recent report examining the meta-
bolic effects of metformin showed that this compound
induces LXRa phosphorylation (at a threonine residue)
in rat pituitary cells, which in turn causes a reduction in
the expression of its target gene Pomc, a precursor of
the adrenocorticotropic hormone, leading to an overall
reduction of systemic cortisol and glucose (52). In this
context, LXRa threonine phosphorylation is shown to
be induced by activated AMPK, which had been pre-
viously associated with the pleiotropic actions of
metformin.
LXR SUMOylation
As the mechanistic basis for the transcriptional re-
pression of proinflammatory genes, Ghisletti et al. (57)
initially demonstrated that ligand-induced SUMOylation
of LXR is required for its interaction with the NCoR
corepressor in mouse primary macrophages and
RAW264.7 macrophage-like cells [Fig. 3(B); Table 1]. In
addition to synthetic ligands, these authors demon-
strated that SUMOylation was promoted by the LXR
endogenous ligands 22(R)-hydroxycholesterol, 24(S),25-
epoxycholesterol, and 24(S)-hydroxycholesterol. In
contrast to PPARg, whose SUMOylation is dependent on
PIAS1 and SUMO1 (97), LXR-mediated transrepression
involves SUMOylation by SUMO2 and SUMO3, with
HDAC4 acting as the SUMO E3 ubiquitin ligase. It was
later shown that the interaction between SUMOylated
LXR and NCoR was facilitated by Coronin 2A, a
member of the actin-binding protein family that acts both
as a docking site for LXR and an exchange factor for
NCoR, proving necessary for the derepression of several
nuclear factor kB–induced proinflammatory gene pro-
moters (58). Moreover, a later study showed that mutant
forms of both LXRs lacking SUMOacceptor sites (LXRa
K328R/K434R and LXRb K410R/K448R) (Fig. 1)
have a decreased capacity to prevent the binding of the
proinflammatory signal transducer and activator of
transcription 1 transcription factor to theNos2 promoter
(59), further establishing the importance of LXR
SUMOylation on its transrepressive capacity. However,
this transrepression model has now been challenged. Ito
et al. (98) recently postulated that repression of in-
flammatory genes by LXRs is dependent on changes in
cellular lipidmetabolism rather than SUMOylation of the
receptor. In their report, the authors proposed a mech-
anism whereby LXR-dependent expression of the aden-
osine triphosphate–binding cassette transporter A1
(ABCA1), which mediates intracellular cholesterol efflux
to apolipoprotein A1, is critical for the repression of
proinflammatory genes by LXR. Increased ABCA1 ex-
pression leads to a decrease inmembrane cholesterol levels
as a result of a higher rate of cholesterol efflux by ABCA1,
thus increasing membrane permeability and disrupting
Toll-like receptor signaling due to the inability of Toll-like
receptors to recruit its signal transducers. This study
demonstrates that LXRs are capable of strong repressive
actions even in the absence of SUMOylation in immor-
talized mouse embryonic fibroblasts in vitro, suggesting
that NR activity is regulated by different independent
pathways. It would be interesting to assess whether this
SUMOylation-independent transrepression mechanism
also occurs in other cell types and under physiological
conditions. Thus, depending on the cell type and disease
context, these 2 models may not be mutually exclusive. In
any case, it still remains unclear what the consequences are
of altering LXR SUMOylation on inflammatory diseases
or other pathophysiological contexts.
These studies highlight the importance of phosphor-
ylation and other PTMs on LXR activity. In the future,
it will be exciting to uncover the exact mechanisms un-
derlying these changes and the impact these have on the
function of the receptor in vivo in the context of meta-
bolic or inflammatory diseases.
RXRs
The RXR family consists of 3 different NRs, encoded
by 3 different genes: RXRa, RXRb, and RXRg (99).
These receptors respond to retinoids (100) or vitamin A
derivatives, although the fact that retinoids have not
been found in animal tissues indicates that RXRs may
also have other endogenous ligands (101). They have the
unique capacity to be able to form homodimers, as well as
heterodimers, with a wide range of other NRs (102),
including LXR and FXR, thus playing a role in a variety
of developmental and metabolic functions.
RXR acetylation
Zhao et al. (60) were the first to show that RXRa and
RXRg are targets of the p300 acetyltransferase, which
induces both cell proliferation and apoptosis in a context-
dependent manner. In the case of RXRa, acetylation at
lysine 125 (Fig. 1) was proven to increase the receptor’s
transcriptional activity in culture by promoting a stronger
binding of the receptor to DNA (Table 1). In their study,
the authors also reported that acetylation ofRXRa by p300
is reduced by the orphan receptor thyroid receptor 3
through competition for RXRa binding. Binding of RXRa
to thyroid receptor 3 was further increased by the RXR
ligand 9-cRA, which led to attenuated p300-induced cell
proliferation via RXRa, suggestive of a crosstalk between
different NRs being modulated by their PTMs.
RXR phosphorylation
Phosphorylation of human RXRa was initially iden-
tified on serine 260, located at the ligand-binding domain
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(Fig. 1) and shown to attenuate its transcriptional acti-
vation through heterodimerization with the vitamin D
receptor in Ras-transformed keratinocytes (103). Phos-
phorylation at Ser260 by the mitogen-activated protein
kinase led, in part, to the resistance of these cells to
growth inhibition by 1,25-dihydroxyvitamin D3, the
active form of vitamin D. Recently, the same group
showed that RXRa phosphorylation at this residue af-
fects the RXRa/vitamin D receptor heterodimer, causing
impaired cofactor recruitment and subsequent reduced
transactivation (Table 1) (61). Phosphorylation of RXRa
on Ser260 is also involved with increased resistance to
proteolysis (104) and loss of heterodimeric activity (64).
Accumulation of this receptor was previously reported on
hepatocellular carcinoma cells (62) and murine hepatic
tumors (105), and it is suspected that the malignancy of
these cells is caused in part by the loss of activity of
phosphorylated RXRa and increased cell proliferation.
Receptor accumulation is due to resistance to proteosomal
degradation by the phosphorylated RXRa form (65).
Consistently, RXRa is highly ubiquitinated in healthy
human liver, whereas in human hepatocarcinoma tissues
and cell lines, the receptor is hyperphosphorylated and thus
resistant to degradation. This strong correlation between
RXRphosphorylation and cellmalignancy led to the notion
of targeting RXRa phosphorylation as a therapy for liver
(106) and colorectal cancers (107). Intriguingly, the same
Ser260 residue is phosphorylated by c-jun N-terminal ki-
nase in response to interleukin-1b, which leads to the rapid
nuclear export and subsequent degradation of RXRa (63).
Several studies have demonstrated that RXRa activity
diminishes in response to anisomycin, a stress stimulus
that inhibits protein synthesis (66, 108). This modulation
of RXRa activity is caused by the activation of the
mitogen-activated protein kinase kinase-4 and its down-
stream kinase c-Jun N-terminal kinase, which phosphor-
ylate RXRa at Tyr249 (108), aswell as 3 different residues
at the AF-1 domain (Ser61, Ser75, and Thr87 or Ser56,
Ser70, and Thr82 in humans) and 1 residue (Ser265 or
Ser260 in humans) located within the AF-2 domain (66).
Notably, similar to LXRa phosphorylation at Ser198 (78),
RXRa phosphorylation at Ser265 inhibits transcription
of a specific subset of RXR target genes in a promoter-
specific manner (66).
Overall, these studies suggest that the impact of RXRa
phosphorylation on the receptor’s activity is dependent
on cell type and experimental conditions. However, the
impact of RXRa phosphorylation on physiology needs
to be further elucidated.
RXR SUMOylation
In addition to the previous modifications, RXRa has
been shown to interact with ubiquitin-conjugating enzyme
9, a SUMO-conjugating E2 enzyme that mediates the
SUMOylation of the receptor (67). RXRa is modified by
SUMO-1, with lysine 108, located in the variable amino-
terminal activation domain (AF-1) region of the receptor
(Fig. 1), being the main SUMO acceptor site. This SUMO
modification of RXRa negatively regulates its transcrip-
tional activity (Table 1) and, interestingly, can be reversed
by the SUMO-specific protease SUSP1, further confirming
the importance of posttranslational modifications as
specific regulators of RXRa activity. A more recent study
showed that RXRa is also SUMOylated in response to
tumor necrosis factor-a stimulation in a human hepato-
cellular carcinoma cell line, suggesting an interesting
crosstalk between proinflammatory stimuli and RXR
activity through the induction of PTMs (68).
As RXRs form heterodimers with a range of other
NRs, including PPARs, LXRs, and FXRs, they hold a
unique potential to play a diverse array of roles mod-
ulating multiple metabolic systems. Likewise, post-
translational modifications of RXR could strongly alter
RXR heterodimer-regulated metabolic pathways. As
studies identifying PTMs in RXR and its heterodimeric
partners continue to emerge, it will be interesting to
explore how combinatorial modifications of these modi-
fications affect the activity of specific heterodimers in
homeostatic as well as altered metabolic states observed
in disease.
Future Perspectives
NRs are involved in a vast range of biological processes,
including metabolism, immunity, development, and re-
production. Their modulatory roles are often dysregulated
in a number of pathologies through several mechanisms,
including changes in their PTMs. Therefore, promoting
these changes as a means to ultimately modulate NR
activity has begun to attract considerable attention. NRs
have been considered important drug targets for de-
cades. Classically, drug development programs have
focused their efforts on the identification of specific li-
gands that either activate or antagonize NR signaling,
sometimes in a context- or tissue-specific manner. As we
learn how posttranslational modifications finely tune
NR actions, and how these PTMs are altered in path-
ological situations, pharmacological or genetic manip-
ulation of these modifications represents an alternative
therapeutic avenue that is starting to be explored.
For example, several studies have now linked the
phosphorylation status of the estrogen receptor a in
breast tumors, with resistance to endocrine treatment and
overall clinical outcomes (109). This is not restricted to
steroid receptors. Recently, based on initial observations
that phosphorylation of PPARg at Ser273 is linked to
doi: 10.1210/en.2016-1577 press.endocrine.org/journal/endo 221
obesity and insulin resistance (110, 111), a drug screening
effort on 780 different Food and Drug Administration–
approved drugs using disruption of PPARg phosphory-
lation as an endpoint (rather than PPARg classical ligand
activation) was reported (112). These efforts identified
that imatinib mesylate (Gleevec), a well-established an-
ticancer drug, increases insulin sensitivity and overall
improves the phenotype of mice fed a high-fat diet by
blocking Ser273 PPARg phosphorylation (112).
Overall, 1 of the remaining challenges that needs to be
addressed is gaining a better understanding of the com-
plex relationships between PTMs in various pathological
contexts in order for the development of these alterna-
tively targeted therapeutics to become a reality for a
larger number of NRs.
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